These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

809 related articles for article (PubMed ID: 31539778)

  • 1. New oxadiazoles with selective-COX-2 and EGFR dual inhibitory activity: Design, synthesis, cytotoxicity evaluation and in silico studies.
    El-Sayed NA; Nour MS; Salem MA; Arafa RK
    Eur J Med Chem; 2019 Dec; 183():111693. PubMed ID: 31539778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rational design-aided discovery of novel 1,2,4-oxadiazole derivatives as potential EGFR inhibitors.
    Unadkat V; Rohit S; Parikh P; Sanna V; Singh S
    Bioorg Chem; 2021 Sep; 114():105124. PubMed ID: 34328857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In Vitro and In Silico Evaluation of Anticancer Activity of New Indole-Based 1,3,4-Oxadiazoles as EGFR and COX-2 Inhibitors.
    Sever B; Altıntop MD; Özdemir A; Akalın Çiftçi G; Ellakwa DE; Tateishi H; Radwan MO; Ibrahim MAA; Otsuka M; Fujita M; Ciftci HI; Ali TFS
    Molecules; 2020 Nov; 25(21):. PubMed ID: 33171861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and synthesis of benzimidazole analogs endowed with oxadiazole as selective COX-2 inhibitor.
    Rathore A; Rahman MU; Siddiqui AA; Ali A; Shaharyar M
    Arch Pharm (Weinheim); 2014 Dec; 347(12):923-35. PubMed ID: 25303727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and biological evaluation of novel indanone containing spiroisoxazoline derivatives with selective COX-2 inhibition as anticancer agents.
    Abolhasani H; Zarghi A; Komeili Movahhed T; Abolhasani A; Daraei B; Dastmalchi S
    Bioorg Med Chem; 2021 Feb; 32():115960. PubMed ID: 33477020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, Synthesis,
    Matada GSP; Abbas N; Dhiwar PS; Basu R; Devasahayam G
    Anticancer Agents Med Chem; 2021; 21(4):451-461. PubMed ID: 32698735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and biological evaluation of a new series of thiazolyl-pyrazolines as dual EGFR and HER2 inhibitors.
    Sever B; Altıntop MD; Radwan MO; Özdemir A; Otsuka M; Fujita M; Ciftci HI
    Eur J Med Chem; 2019 Nov; 182():111648. PubMed ID: 31493743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and anticancer evaluation of thieno[2,3-d]pyrimidine derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers.
    Elmetwally SA; Saied KF; Eissa IH; Elkaeed EB
    Bioorg Chem; 2019 Jul; 88():102944. PubMed ID: 31051400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In silico design, synthesis and activity of potential drug-like chrysin scaffold-derived selective EGFR inhibitors as anticancer agents.
    Debnath S; Kanakaraju M; Islam M; Yeeravalli R; Sen D; Das A
    Comput Biol Chem; 2019 Dec; 83():107156. PubMed ID: 31710991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel 1,3,4-oxadiazole derivatives of naproxen targeting EGFR: Synthesis, molecular docking studies, and cytotoxic evaluation.
    Alsaad HN; Al-Jasani BM; Mahmood AAR; Tahtamouni LH; Saleh KM; AlSakhen MF; Kanaan SI; Yasin SR
    Drug Dev Res; 2024 Aug; 85(5):e22231. PubMed ID: 38956926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 1,3,4-oxadiazole/chalcone hybrids: Design, synthesis, and inhibition of leukemia cell growth and EGFR, Src, IL-6 and STAT3 activities.
    Fathi MAA; Abd El-Hafeez AA; Abdelhamid D; Abbas SH; Montano MM; Abdel-Aziz M
    Bioorg Chem; 2019 Mar; 84():150-163. PubMed ID: 30502626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
    El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
    Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, in vitro and in silico evaluation of a new series of oxadiazole-based anticancer agents as potential Akt and FAK inhibitors.
    Altıntop MD; Sever B; Akalın Çiftçi G; Turan-Zitouni G; Kaplancıklı ZA; Özdemir A
    Eur J Med Chem; 2018 Jul; 155():905-924. PubMed ID: 29966916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, chemical characterization, biological evaluation, and docking study of new 1,3,4-oxadiazole homonucleoside analogs.
    El Mansouri AE; Maatallah M; Ait Benhassou H; Moumen A; Mehdi A; Snoeck R; Andrei G; Zahouily M; Lazrek HB
    Nucleosides Nucleotides Nucleic Acids; 2020; 39(8):1088-1107. PubMed ID: 32397827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New pyrimidine and pyrazole-based compounds as potential EGFR inhibitors: Synthesis, anticancer, antimicrobial evaluation and computational studies.
    Othman IMM; Alamshany ZM; Tashkandi NY; Gad-Elkareem MAM; Anwar MM; Nossier ES
    Bioorg Chem; 2021 Sep; 114():105078. PubMed ID: 34161878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel Phenolic Compounds as Potential Dual EGFR and COX-2 Inhibitors: Design, Semisynthesis, in vitro Biological Evaluation and in silico Insights.
    Abdelgawad MA; Musa A; Almalki AH; Alzarea SI; Mostafa EM; Hegazy MM; Mostafa-Hedeab G; Ghoneim MM; Parambi DGT; Bakr RB; Al-Muaikel NS; Alanazi AS; Alharbi M; Ahmad W; Bukhari SNA; Al-Sanea MM
    Drug Des Devel Ther; 2021; 15():2325-2337. PubMed ID: 34103896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New Ferrocene Compounds as Selective Cyclooxygenase (COX-2) Inhibitors: Design, Synthesis, Cytotoxicity and Enzyme-inhibitory Activity.
    Farzaneh S; Zeinalzadeh E; Daraei B; Shahhosseini S; Zarghi A
    Anticancer Agents Med Chem; 2018; 18(2):295-301. PubMed ID: 28971779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and Synthesis of some new 2,4,6-trisubstituted quinazoline EGFR inhibitors as targeted anticancer agents.
    Allam HA; Aly EE; Farouk AKBAW; El Kerdawy AM; Rashwan E; Abbass SES
    Bioorg Chem; 2020 May; 98():103726. PubMed ID: 32171987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and anticancer evaluation of 1H-pyrazolo[3,4-d]pyrimidine derivatives as potent EGFR
    Gaber AA; Bayoumi AH; El-Morsy AM; Sherbiny FF; Mehany ABM; Eissa IH
    Bioorg Chem; 2018 Oct; 80():375-395. PubMed ID: 29986185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies.
    Abd El-Meguid EA; Naglah AM; Moustafa GO; Awad HM; El Kerdawy AM
    Bioorg Med Chem Lett; 2022 Feb; 58():128529. PubMed ID: 35007724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.